Foxo Technologies (FOXO) investor relations material

Company overview and business model

• Operates in healthcare services and technology, with segments in Healthcare, Life Science Services, and Labs, each with synergistic divisions including rural hospitals, behavioral health, biospecimens, and epigenetic diagnostics.

• Recent acquisitions include Myrtle Recovery Centers (behavioral health), RCHI/SCCH (rural hospital), and Vector BioSource (biospecimen sourcing and data services).

• Labs segment focuses on commercializing epigenetic biomarker technology, leveraging AI and machine learning for health and wellness insights.

• Strategy includes growth by acquisition, expansion of behavioral health facilities, and commercialization of proprietary technology.

Financial performance and metrics

• For 2024, net revenues were $4.05M with a net loss attributable to common stockholders of $13.56M; pro-forma combined net revenues (including acquisitions) were $12.06M with a net loss of $16.77M.

• Cash and cash equivalents were $628,557 as of September 30, 2025, and $68,268 as of December 31, 2024.

• The company has a history of significant operating losses and negative cash flows, with a going concern warning from auditors.

Use of proceeds and capital allocation

• Will not receive proceeds from the resale of shares by the selling stockholder; may receive up to $5M in gross proceeds from ClearThink under the Purchase Agreement if all shares are issued.

• Proceeds, if received, are expected to be used for general corporate purposes, including working capital and administrative expenses.